Increasing the efficiency of clinical trials in neurodegenerative disorders using group sequential trial designs

Clinical trials in neurodegenerative disorders are facing high futility rates and rising development costs. We aim to review and exemplify the value of group sequential trial designs (i.e. designs with one or more prospectively planned interim analyses) within the field of amyotrophic lateral sclerosis (ALS).

Source: Journal of Clinical Epidemiology - February 24, 2018 Category: Epidemiology Authors: Ruben P.A. van Eijk, Stavros Nikolakopoulos, Toby A. Ferguson, Dawei Liu, Marinus J.C. Eijkemans, Leonard H. van den Berg Source Type: research